Trial Information

Summary: A Phase I study or SGX523 in Patients with Advanced Cancer

The purpose of this study is to determine the safety and tolerability of SGX523 when administered to patients with advanced solid tumors. The study will assess the effects of the drug on patients and their cancers by assessing patients' side effects and through pharmacokinetics. Pharmacokinetics (PKs) is a way to determine the level of drug in the patient's blood and to study how the body processes, distributes, metabolizes and eliminates the drug. This is done by frequent blood draws during the first four weeks of treatment.

SGX523 is a targeted therapy and is an oral, ATP-competitive small molecule inhibitor of MET, a pathway used to allow cancer cells to grow. SGX523 is not approved by the FDA and is considered investigational in this study.

Patient Inclusion Criteria:

• Advanced solid tumors
• Coagulation allowed if stable PT/PTT for 14 days before starting

Not all eligibility criteria are listed. Additional criteria must be met in order to be eligible.

Patient Exclusion Criteria:

• Brain mets unless stable for 3 months
• Bilirubin and creatinine within normal limits

If you would like to learn more about participating in this study, please send an e-mail message using the form below.